Acarix

Acarix EBITDA per Employee

The EBITDA per Employee of Acarix (ACARIX.ST) as of Nov 12, 2026 is -5.33 M SEK. In the previous year, EBITDA per Employee was -7.37 M SEK — a change of -27.66% (higher).

EBITDA per Employee

-5.33 MSEK

YoY

-27.66%

Last updated:

EBITDA per Employee of Acarix is 2025 -5.33 M SEK. EBITDA per Employee of Acarix was 2024 -7.37 M SEK. It decreases by -27.66% higher compared to the previous year.

The Acarix EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-4.72 M SEK
Jan 1, 2019
-5.16 M SEK
Jan 1, 2020
-4.60 M SEK
Jan 1, 2021
-5.74 M SEK
Jan 1, 2022
-8.54 M SEK
Jan 1, 2023
-8.62 M SEK
Jan 1, 2024
-7.37 M SEK
Jan 1, 2025
-5.33 M SEK
The Acarix EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-5.33 MSEK-27.66%
-7.37 MSEK-14.42%
-8.62 MSEK+0.93%
-8.54 MSEK+48.63%
-5.74 MSEK+24.74%
-4.60 MSEK-10.76%
-5.16 MSEK+9.22%
-4.72 MSEK+38.32%
-3.42 MSEK+14.59%
-2.98 MSEK+74.47%
-1.71 MSEK-35.90%
-2.67 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

EBITDA per Employee of Acarix is -5.33 M SEK in 2025.

EBITDA per Employee of Acarix changed from -7.37 M SEK to -5.33 M SEK, representing a -27.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Acarix since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Acarix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Acarix

All Key Metrics — Acarix